A Study of the SMART Stent in the Treatment SFA Disease. (SIROCCO)

This study has been completed.
Sponsor:
Information provided by:
Cordis Corporation
ClinicalTrials.gov Identifier:
NCT00232869
First received: October 4, 2005
Last updated: February 3, 2010
Last verified: February 2010
  Purpose

The main objective of this study is to assess the safety and performance of the sirolimus coated Cordis SMART™ nitinol self expandable stent device and its delivery system in the treatment of obstructive superficial femoral artery (SFA) disease in reducing percent in-stent mean lumen diameter stenosis in de novo or restenotic native lesions as compared to the uncoated SMART™ stent.


Condition Intervention Phase
Peripheral Artery Disease
Device: drug-eluting stent
Device: bare-metal stent
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Clinical Investigation of the SIROlimus Coated Cordis SMART™ Nitinol Selfexpandable Stent for the Treatment of Obstructive Superficial Femoral Artery Disease.

Resource links provided by NLM:


Further study details as provided by Cordis Corporation:

Primary Outcome Measures:
  • In-stent mean lumen diameter percent stenosis via quantitative angiography. [ Time Frame: 6 months. ] [ Designated as safety issue: Yes ]

Enrollment: 93
Study Start Date: February 2001
Study Completion Date: May 2009
Primary Completion Date: June 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
Device: drug-eluting stent
Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
Active Comparator: 2
SMART™ bare-metal stent
Device: bare-metal stent
SMART™ bare-metal stent

Detailed Description:

This is a multi-center, prospective, randomized, double blind, two-arm feasibility study evaluating the safety and performance of the sirolimus coated Cordis SMART™ nitinol self-expanding stent and delivery system as compared to the uncoated SMART™ stent and delivery system. It is anticipated that a total of 90 patients will be entered into the study. Patients will be randomized on a 1:1 basis of coated to uncoated stents.

Ninety (90) patients with de novo or restenotic native SFA lesions will be randomized to the Sirolimus Coated SMART™ nitinol self-expanding stent or to the uncoated (bare) SMART™ stent.

Patients will be followed for 24 months post-procedure, with all patients having duplex ultrasound and clinical assessments at discharge, 1, 6, 9, 18 and 24 months, angiography at 6 six months and plain X-ray at 18 months. This study will be conducted at nine investigational sites. (Protocol was amended where 56 additional patients were recruited and followed for up to 5 years.)

  Eligibility

Ages Eligible for Study:   30 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. One superficial femoral artery presenting > 70% stenosis(es) or total occlusion
  2. Symptomatic leg ischemia by Rutherford Classification (category 1, 2, 3 or 4)

Exclusion Criteria:

  1. Tissue loss due to ischemic disease (Rutherford category 5 or 6).
  2. Tandem lesion requiring non overlapping stents;
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00232869

Locations
Germany
University Hospital
Tübingen, Germany, 72070
Sponsors and Collaborators
Cordis Corporation
Investigators
Principal Investigator: Stephan H Duda, MD Tübingen - Germany
  More Information

Publications:
Responsible Party: Dr. Hans-Peter Stoll, Cordis
ClinicalTrials.gov Identifier: NCT00232869     History of Changes
Other Study ID Numbers: EE00-02
Study First Received: October 4, 2005
Last Updated: February 3, 2010
Health Authority: Germany: Ethics Commission
France: Institutional Ethical Committee
Netherlands: Independent Ethics Committee
United Kingdom: Research Ethics Committee
Canada: Ethics Review Committee
Australia: Human Research Ethics Committee

Additional relevant MeSH terms:
Peripheral Arterial Disease
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Peripheral Vascular Diseases
Sirolimus
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Antifungal Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents

ClinicalTrials.gov processed this record on July 29, 2014